- 31 Aug. | Upcoming programs by forumiAS For UPSC CSE 2027 Click Here to Read More →
- 23 August | Your preparation may need an environment, not another course Click Here to Read More →
- 17 August | Navigating the Crest & Trough of Rankforgers by Mr. Ayush Sinha Click Here to Watch →
Contents
Source: The post is based on the article “DRDO-developed technology behind critical drug approved by DCGI for radiological and nuclear emergencies” published in The Hindu on 16th March 2023
What is the News?
The Defence Ministry has announced that the Prussian blue insoluble formulations drug has been granted approval by the Drugs Controller General of India(DCGI).
What is a Prussian blue insoluble formulation drug?
It is one of the critical medicines listed by the World Health Organisation(WHO) for radiological and nuclear emergencies.
It is used to treat the symptoms of Cesium or Thallium Contamination.
The drug was developed under the Technology Development Fund(TDF).
The drug has been developed based on the technology of the Institute of Nuclear Medicine and Allied Sciences (INMAS), Delhi, a laboratory of the DRDO.
